(LLYX) Defiance Daily Target 2X - Overview
ETF Category: Trading--Leveraged Equity | Exchange: NYSE ARCA (USA) | Market Cap: 37m USD | Total Return: 86.7% in 12m
Avg Turnover: 11.9M
Warnings
Extended 1w
Tailwinds
No distinct edge detected
LLYX is an actively managed, non-diversified ETF designed to provide 200% of the daily price performance of Eli Lilly and Company (LLY). The fund achieves this leveraged exposure through the use of financial derivatives, specifically swap agreements and listed options contracts.
Eli Lilly operates within the pharmaceutical sector, a capital-intensive industry driven by long-term research and development cycles and patent protections. The companys business model focuses on the discovery and manufacturing of human pharmaceuticals, particularly in high-growth therapeutic areas such as metabolic disorders and oncology.
For a deeper look into the underlying fundamentals of the pharmaceutical industry, consider exploring the data on ValueRay.
- Eli Lilly weight loss drug sales drive underlying stock volatility
- Mounjaro and Zepbound market penetration impacts leverage returns
- FDA regulatory approvals for obesity and Alzheimers pipelines dictate momentum
- Compounding pharmacy competition threatens market share and revenue growth
- High interest rates increase financing costs for leveraged swap agreements
As of May 29, 2026, the stock is trading at USD 24.97 with a total of 559,917 shares traded.
Over the past week, the price has changed by +22.10%,
over one month by +62.35%,
over three months by +7.77% and
over the past year by +86.71%.
Defiance Daily Target 2X has no consensus analysts rating.